Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors -Pipeline Insights, 2015

“Summary
DelveInsight’s, Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight’s, Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors- Pipeline Insights, 2015 Report covers the Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
”
“Scope
– DelveInsight’s report provides a Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Landscape across the globe
– The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
– Coverage of the Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
– The report reviews key players involved in the therapeutics development for Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors and also provide company profiling
– Pipeline products coverage based on various stages of development from NDA filings to discovery.
– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
”
“Reasons to buy
– Complete Pipeline intelligence and complete understanding over therapeutics development for Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors
– Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
– Track your competitors and develop strategic initiatives to support your drug development activities.
– Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
– Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
– Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned
”

“• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Overview
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Disease Associated
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Pipeline Therapeutics
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Therapeutics under Development by Companies 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Late Stage Products (Filed and Phase III)
• Comparative Analysis 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Mid Clinical Stage Products (Phase II)
• Comparative Analysis 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Discovery and Pre-Clinical Stage Products 
• Comparative Analysis 
• Drug Candidate Profiles
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors – Therapeutics Assessment 
• Assessment by Monotherapy Products 
• Assessment by Combination Products 
• Assessment by Route of Administration 
• Assessment by Molecule Type 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors – Discontinued Products 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors 
• Appendix 
• Methodology 
• Contact Us 
• Disclaimer”
“• Number of Products under Development for Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors by Therapy Area, 2015
• Number of Products under Development for Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors, 2015
• Number of Products under Development by Companies 
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Assessment by Monotherapy Products 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Assessment by Combination Products 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Assessment by Route of Administration 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Assessment by Stage and Route of Administration 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Assessment by Molecule Type 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Assessment by Stage and Molecule Type 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Therapeutics – Discontinued Products 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2015″
“• Number of Products under Development for Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors by Therapy Area, 2015
• Number of Products under Development for Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors, 2015
• Late Clinical Stage Products (Filed and Phase III), 2015
• Mid Clinical Stage Products (Phase II), 2015
• Early Clinical Stage Products (Phase I and IND Filed), 2015
• Discovery and Pre-Clinical Stage Products, 2015
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Assessment by Monotherapy Products 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Assessment by Combination Products 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Assessment by Route of Administration 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Assessment by Stage and Route of Administration 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Assessment by Molecule Type 
• Integrin Alpha4beta1/Very Late Antigen-4 (VLA-4) Inhibitors Assessment by Stage and Molecule Type”